Key Takeaways
- BiomEdit received foundational patents including “Genetically Modified Lactobacillus and Uses Thereof” (U.S. Patent 12,599,637) and “Probiotic Compositions Comprising Lactobacillus reuteri Strains and Methods of Use” (U.S. Patent 12,427,174).
- The patents protect engineered Lactobacillus reuteri strains capable of expressing therapeutic biomolecules and delivery systems for localized payload expression.
- BE-101, BiomEdit’s lead probiotic vectored antibody biologic, targets Clostridium perfringens toxins to prevent necrotic enteritis in broiler chickens.
- BiomEdit anticipates conditional USDA licensure for BE-101 in Q3 2026 with commercial readiness aligned to Q4 2026.
- The company was founded in 2022 and is backed by investors including Anterra Capital, Viking Global, Nutreco, AgriZeroNZ, Elevate and Betagro Ventures.
BiomEdit Patent Portfolio Establishes Platform Protection
The newly issued patents establish comprehensive protection for BiomEdit’s engineered probiotic delivery platform. The patents cover engineered Lactobacillus reuteri strains capable of expressing therapeutic biomolecules in situ, delivery systems enabling localized and sustained payload expression, and expression of biologically active proteins including novel antibodies targeting Clostridium perfringens.
The patent portfolio extends beyond poultry applications, covering multiple species spanning livestock, pets and human health. This broad protection secures the core technology underlying BiomEdit’s probiotic vectored delivery platform and establishes a foundation for developing precision biologics delivered through well-characterized microbial strains.
BE-101 Advances Toward USDA Conditional Licensure
BiomEdit’s lead product BE-101 represents a first-of-its-kind probiotic vectored antibody (pvAb™) biologic designed to neutralize Clostridium perfringens toxins, a primary driver of necrotic enteritis in broiler chickens. The therapy delivers targeted biomolecules directly within the gastrointestinal tract, offering a non-antibiotic approach to disease prevention and production improvement.
BE-101 is currently progressing through field studies and regulatory review with the U.S. Department of Agriculture‘s Center for Veterinary Biologics. The company anticipates conditional licensure in Q3 2026, subject to standard regulatory review timelines, with commercial readiness aligned to Q4 2026.
BiomEdit Platform Enables Broader Applications
Beyond BE-101, BiomEdit’s platform enables applications including disease prevention, performance enhancement and therapeutic approaches across animal health, with potential extension into human health. The company’s approach integrates strain engineering, payload design and scalable oral delivery, positioning BiomEdit to advance microbiome-enabled biologics as alternatives to traditional therapeutics.
Founded in 2022, BiomEdit leverages synthetic biology and microbiome science to develop solutions for livestock and pet health, backed by investors including Anterra Capital, Viking Global, Nutreco, AgriZeroNZ, Elevate and Betagro Ventures.
